
Informa TechTarget and Salesloft Announce Strategic Partnership to Help Customers Grow Revenue Through Precise, Data-Driven Prospecting
NEWTON, Mass. & ATLANTA--(BUSINESS WIRE)--TechTarget, Inc. ("Informa TechTarget") (Nasdaq: TTGT), global growth accelerator and leading provider of intent data and insights to the B2B technology sector, and Salesloft, a leading Revenue Orchestration Platform that helps B2B organizations drive durable revenue growth, today announced a partnership and integration designed to help mutual customers build and accelerate pipeline by efficiently identifying and effectively engaging prospects in an active buying journey.
'While 85% of BDRs are laser-focused on outbound prospecting, many of them waste precious cycles pursuing cold contacts who aren't ready to buy. We help reps hit their pipeline targets by identifying buyers who are actively researching relevant solutions through their membership to our trusted editorial communities,' said Jillian Coffin, Senior Vice President of Customer Enablement and Strategy, Informa TechTarget. 'By automatically delivering these active, permissioned contacts into topically aligned Salesloft cadences, we help sellers engage the right people with the right message at the right time so they can convert more interest into opportunity.'
The new integration empowers sales teams to:
Streamline workflows between Informa TechTarget and Salesloft to maximize sales efficiency
Easily add Active Prospects from Informa TechTarget's Priority Engine intent data platform directly into relevant Salesloft cadences in seconds
Automatically push Active Prospects to topically aligned Salesloft cadences each week
"The combination of Informa TechTarget's active, permissioned contacts with Salesloft's engagement capabilities gives sales teams a meaningful advantage," said Lesley Renna, SVP of Alliances and Ecosystem at Salesloft. "This integration helps our joint customers drive higher productivity and conversion rates by automatically adding prospects in an active buying cycle to Salesloft Cadences tailored to the topics that matter most to them."
Key benefits of this strategic partnership include:
Precision targeting: Customers can leverage Informa TechTarget's person-level intent data to confidently focus sellers on in-market buyers and buying groups in their territory or ABM targets.
Accelerated engagement: Informa TechTarget constantly monitors for new individuals beginning their research journey and automatically delivers these permissioned buyers to Salesloft, drastically reducing the time between intent signals and sales outreach.
Higher conversion: With Informa TechTarget, sellers get visibility into the needs, pain points, and current topics of interest for each individual buyer so they can better personalize across every touchpoint, which helps them book more meetings and have meaningful conversations that convert.
'The Add to SEP feature integration between Priority Engine and Salesloft is impressively intuitive. I love how new additions appear right at the top in Salesloft,' said Theresa Woodiel, Director, ABM & Integrated Marketing at Deep Instinct. 'The seamless workflow means our reps can instantly see and engage with their newest priority contacts. It's exactly the kind of straightforward, efficient solution our team needs.'
The Informa TechTarget-Salesloft integration is available now to current Priority Engine Sales subscribers at no additional cost. Customers must have both a Priority Engine Sales subscription and a Salesloft license to utilize the integration. To learn more, click here.
About Informa TechTarget
TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI.
With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market.
Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients:
Trusted information that shapes the industry and informs investment
Intelligence and advice that guides and influences strategy
Advertising that grows reputation and establishes thought leadership
Custom content that engages and prompts action
Intent and demand generation that more precisely targets and converts
Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit informatechtarget.com and follow us on LinkedIn.
About Salesloft
Salesloft powers durable revenue growth for the world's most demanding companies. Salesloft's industry-leading Revenue Orchestration Platform uses purpose-built AI to help market-facing teams prioritize and take action on what matters most, from first touch to upsell and renewal. More than 5,000 customers including Google, 3M, IBM, Shopify, Square, and Cisco gain a performance force multiplier with Salesloft by shifting to a durable revenue engagement model, helping them solve the complexities of modern B2B sales and unlock revenue efficiency.
© 2025 TechTarget, Inc d/b/a Informa TechTarget. All rights reserved. All trademarks are the property of their respective owners.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Stock market today: Dow, S&P 500 and Nasdaq futures rise as stocks set to end June with a bang
US stock futures edged higher Sunday evening, setting up the major indexes for more records to end one of the most volatile first halves of a year in recent memory. Futures tied to the Dow Jones Industrial Average (YM=F) rose around 0.5%. Contracts on the S&P 500 (ES=F) gained 0.2%, and Nasdaq 100 (NQ=F) futures ticked up 0.3%. Several of Trump's economic agenda items are in focus this week. A July 9 deadline looms before the possible resumption of Trump's unilateral tariffs, which Trump on Sunday said he didn't think he'd "need to" extend. On the trade front, India has extended its Washington visit to finalize a deal. Administration officials last week confirmed a trade framework with China was in place, bolstering investor sentiment despite a late-Friday dip triggered by Trump's abrupt halt to talks with Canada, citing its digital tax policy. Meanwhile, market watchers are closely following Senate negotiations over Trump's proposed $4.5 trillion tax cut bill. The measure, which passed a procedural vote Saturday, could face a tough path in the House. The Congressional Budget Office estimates it would add $3.3 trillion to the deficit over a decade. For the market, June's gains have been substantial, fueled by optimism surrounding global trade and easing fears over tariffs. The S&P 500 (^GSPC) is up over 4%, the Nasdaq Composite (^IXIC) has surged over 5.5%, and the Dow (^DJI) has climbed 3.5%. On Friday, all three major indexes closed higher, with the S&P and Nasdaq reaching new record highs for the first time since February — the start of the year's tariff-fueled stock swings. All three major indexes are up at least 3% so far this year. Looking ahead, investors will monitor key Chinese PMI data due Monday to gauge how the ongoing trade war is affecting Asia's largest economy. Despite lingering uncertainties, the broader market remains upbeat heading into the new quarter and second half.
Yahoo
4 hours ago
- Yahoo
Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements
DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ('Portage' or the 'Company') (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands ('Portage'), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. About Portage BiotechPortage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system's ability to fight cancer. For more information, visit Forward-Looking StatementsAll statements in this news release, other than statements of historical facts, including without limitation, statements regarding the Company's business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise include the words 'believe,' 'expects,' 'anticipates,' 'intends,' 'estimates,' 'will,' 'may,' 'plans,' 'potential,' 'continues,' or similar expressions or variations on such expressions are forward-looking statements. As a result, forward-looking statements are subject to certain risks and uncertainties, including, but not limited to: the risk that the Company may not secure financing, the uncertainty of the Company's ability to continue as a going concern, scientific results may not be as expected, and other factors set forth in 'Item 3 - Key Information-Risk Factors' in the Company's Annual Report on Form 20-F for the year ended March 31, 2024 and 'Business Environment – Risk Factors' in the Company's Management's Discussion and Analysis for the Three and Six Months ended September 30, 2024, filed as Exhibit 99.2 to the Company's Form 6-K. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law. For More Information:Portage BiotechAlexander Pickett, Chief Executive Officerir@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
5 hours ago
- Yahoo
Is Tesla Stock a Millionaire Maker?
In the past 15 years, this top EV stock has climbed more than 20,000%. Tesla shares have always sold for a premium, which is detached from the reality of the current business. Investors considering buying the stock must believe the company will make good on its plans for autonomous driving and robotics. These 10 stocks could mint the next wave of millionaires › Looking back at its history as a public company, Tesla (NASDAQ: TSLA) has generated serious wealth for investors. The auto industry disruptor has seen its shares skyrocket 20,290% since its initial public offering in June 2010 (as of June 25). Had you invested just $5,000 back then, there would be a $1 million balance in your portfolio right now. No one would argue with that kind of impressive past gain. But will the leading EV stock be a millionaire maker in the future? Tesla might be the most closely watched business in the world, partly, because of how it disrupted the global car market. Investors also keep tabs on what CEO Elon Musk is doing, as well as his plans for the company (more on this below). However, investors shouldn't lose sight of what Tesla really is today, which is a challenged company that sells innovative and tech-enhanced EVs. In the first quarter, the business reported $14 billion of automotive revenue, 72% of the total. Total revenue was up just 0.9% in 2024, then it declined 9.2% in Q1 2025. Operating income in the first quarter tanked 66%, thanks to lower average selling prices, fewer deliveries, and higher expenses. To be fair, this is an extremely inventive company that's working at the cutting edge of exciting technologies. But someone viewing Tesla with a clear lens would see that this is a struggling business. Its core operations are under pressure, without a doubt. What valuation should Tesla trade at knowing the reality of the business today? Even with a more reasonable price-to-earnings ratio (P/E) of 50 (compared to its current P/E ratio of 179), which is what luxury automaker Ferrari trades for, the stock has 72% downside. That certainly doesn't give investors any reason to be bullish. Based on the current market cap of $1 trillion and P/E ratio of 179, Tesla is wildly overvalued. But the story stock has seemingly always traded at a steep valuation, as investors continue to bet on a future that sees the company realizing its potential as a dominant force in autonomous driving and robotics. The company has finally launched a robotaxi service in Austin, Texas. This was highly anticipated and something that Musk has talked about for years. However, I think it turned out to be a big nothing burger. There were no Cybercabs. Less than two dozen Model Ys were used instead. There were human supervisors in all the vehicles. And videos of the robotaxis in action showed numerous issues, spurring an investigation by the National Highway Traffic Safety Administration. At the same time, Alphabet's Waymo is handling 250,000 trips per week in multiple cities. And an application is in place to start testing the service in New York City. Tesla appears to still have a long way to go. The company is also leveraging its AI capabilities to work on Optimus, a humanoid robot. Musk believes it will produce 1 million units annually by the end of this decade. Besides placing these machines in its factories, the goal is to sell them to other companies. If all goes according to plan, which is a very uncertain outcome, then Tesla could make its investors into millionaires down the road. The end markets for robotaxis and humanoid robots are estimated to be measured in the trillions of dollars. The company's ability to not only have these technologies achieve mass adoption, but to also capture a sizable chunk of the opportunity, could create a financial windfall. However, I think there's also a good chance that the business won't deliver up to its heightened expectations, a perspective that's supported by a history of constant delays. This is a stock that I'm still avoiding. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $409,114!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,173!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $713,547!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 23, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet and Tesla. The Motley Fool has a disclosure policy. Is Tesla Stock a Millionaire Maker? was originally published by The Motley Fool